I'm LongbridgeAI, I can summarize articles.Hong Kong's overlooked small-caps are showing quiet momentum in medical innovation and cross-border expansion. EDGE MEDICAL-B (2675.HK) made headlines as its surgical robot completed Singapore's first commercial installation at Farrer Park Hospital in late September—a milestone for Chinese robotics entering Southeast Asia's healthcare infrastructure. The move aligns with its global footprint across 60+ markets, though FY2025 revenue remained modest at RMB 455.7 million.
Medical AI players gained traction as Anthropic and OpenAI slashed API costs. Qingsong Health (2661.HK) accelerated commercialization of its Zhengjing voice-recording tools for clinical documentation, leveraging cost efficiencies to scale its RMB 1.256 billion FY2025 revenue base. Meanwhile, China Resources Pharmaceutical (3320.HK) secured dual RMB 10 billion distribution partnerships with Sinopharm and SBP GROUP, while its brexpiprazole 原料药 approval signaled pipeline progress.
Banking and fintech saw structural shifts. China Minsheng Bank (1988.HK) launched its Min Ying Zhi Yuan brand amid S&P-led rating upgrades, though a Kunming branch penalty highlighted operational risks. BAIGE DIGITAL (2672.HK) advanced H-share full circulation plans, converting 170 million domestic shares to boost liquidity. Pangaea Connectivity Technology (1473.HK) reported steady 4.77% FY2026 revenue growth after relocating its Hong Kong office.
Other names like Tong Ren Tang Care (2667.HK) and IMPACT THERAPEUTICS-B (7630.HK) traded quietly but outperformed the Hang Seng Index weekly. The sector's resilience amid sparse coverage suggests latent value in niche healthcare and trade-focused models.
